Gene expression signatures (GES) derived from digital histology to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (CT) in ISPY2 and other trial/real world cohorts.
Howard F, Babu R, Dolezal J, Huo D, Borowsky A, Symmans W, Campbell M, Wolf D, Hirst G, Venters S, Asare A, Kanaparthi S, Blenman K, Shan N, Perou C, Esserman L, van t Veer L, Pusztai L, Nanda R, Pearson A. Gene expression signatures (GES) derived from digital histology to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (CT) in ISPY2 and other trial/real world cohorts. Journal Of Clinical Oncology 2025, 43: 587-587. DOI: 10.1200/jco.2025.43.16_suppl.587.Peer-Reviewed Original ResearchPathological complete responseLikelihood of pathologic complete responseGene expression signaturesHR statusPattern of lymphocyte infiltrationStandard of care CTPredicting pathologic complete responsePrediction of response to therapyHormone receptorsPathologic complete response predictionImprove treatment personalizationPre-treatment biopsiesTime of biopsyResponse to therapyBreast cancer subtypesEstrogen-regulated genesBenjamini-Hochberg correctionNeoadjuvant cohortNeoadjuvant CTYale cohortComplete responseNeoadjuvant chemotherapyPCR rateNodal stagingBreast cancer signatures
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply